Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
158.00    1.50 (0.96%)
Bid:
155.00
Ask:
158.00
Spread: 3.00 (1.935%)
Market Cap: £1.36b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Director/PDMR Shareholding

22 May 2007 07:00

Hutchison China Meditech Limited22 May 2007 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Director's Shareholding London: Tuesday, 22 May 2007: Chi-Med was informed on 18 May 2007 that Mr.Christian Hogg, Executive Director and Chief Executive Officer of Chi-Med,purchased 70,000 ordinary shares of US$1 each in Chi-Med (the "Shares") at aprice of 153p each on 18 May 2007. Following this purchase, Mr. Hogg is beneficially interested in 170,000 Sharesand vested option to subscribe for up to 384,091 Shares, representingapproximately 1.1% of the current issued share capital of Chi-Med. Ends Enquiries Chi-Med Telephone: +852 2121 8200 Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571 Anthony Carlisle Mobile: +44 (0) 7973 611 888 Yvonne Alexander Mobile: +44 (0) 7866 610 682 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med is focused onresearching, developing, manufacturing, and selling pharmaceuticals, healthsupplements and other consumer health and personal care products derived fromTraditional Chinese Medicine and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Jul 20157:00 amRNSInvention patent granted for SXBXP
6th Jul 20157:00 amRNSNotice of Announcement of 2015 Interim Results
29th Jun 20157:00 amRNSBlocklisting Six Monthly Return
1st Jun 20157:00 amRNSSavolitinib preliminary Phase Ib data presented
13th May 20157:00 amRNSFruquintinib results trigger payments from Lilly
30th Apr 20157:00 amRNSTotal Voting Rights
24th Apr 201512:40 pmRNSResult of AGM
22nd Apr 201511:23 amRNSDirector/PDMR Shareholding
16th Apr 20151:19 pmRNSDirector's Shareholding
13th Apr 20158:07 amRNSDirector's Shareholding
8th Apr 20158:18 amRNSDirectors' Shareholding
1st Apr 20153:48 pmRNSDirectors Shareholding
1st Apr 20152:32 pmRNSExercise of Options
30th Mar 20157:00 amRNSTrial of fruquintinib achieves primary endpoint
23rd Mar 20157:00 amRNSNotice of AGM
18th Mar 20157:08 amRNSNotification of Major Interest in Shares
6th Mar 20157:06 amRNSPatient enrolment completion for Phase II study
26th Feb 20157:00 amRNSFinal Results
29th Jan 20157:00 amRNSDistribution Agreement for Seroquel in China
26th Jan 20157:00 amRNSNotice of Results
31st Dec 20147:00 amRNSTotal Voting Rights
29th Dec 20147:00 amRNSBlocklisting Six Monthly Return
15th Dec 20147:00 amRNSInitiation of fruquintinib Phase III study
31st Oct 20147:03 amRNSTotal Voting Rights
7th Oct 20147:00 amRNSDrug R&D Update Briefing
1st Oct 20147:00 amRNSCo-promotion agreement with Merck Serono
19th Sep 20149:13 amRNSHolding(s) in Company
21st Aug 20147:00 amRNSPatient enrolment in Phase II study completed
13th Aug 20147:00 amRNSHMPL-004 Interim Analysis
29th Jul 20147:00 amRNSInterim Results
30th Jun 20147:00 amRNSBlocklisting Interim Review
30th Jun 20147:00 amRNSTotal Voting Rights
26th Jun 20147:00 amRNSNotice of Results
25th Jun 20147:00 amRNSChi-Med Refinancing of Existing Loan Facility
18th Jun 20147:00 amRNSStart of Phase I clinical trial with HMPL-523
5th Jun 20147:00 amRNSInitiation of fruquintinib Phase II study
4th Jun 20141:52 pmRNSDirector's Shareholding
3rd Jun 20143:23 pmRNSExercise of Options
30th May 20149:10 amRNSGains rights to six prescription drug products
23rd May 20147:00 amRNSInitiation of Phase II Study in Renal Cancer
22nd May 20147:00 amRNSPhase I data to be presented at ASCO
8th May 201411:54 amRNSResult of AGM
17th Apr 20147:00 amRNSChi-Med and Sinopharm Deal Approved
4th Apr 20147:00 amRNSInitiation of Phase II study in colorectal cancer
4th Apr 20147:00 amRNSPresentations at the 2014 AACR Annual Meeting
28th Mar 20147:00 amRNS2013 Annual Report and Notice of AGM
18th Feb 20147:00 amRNSFinal Results
13th Feb 20148:14 amRNSNotification of Major Interest in Shares
16th Jan 20147:00 amRNSNotice of Results
30th Dec 20137:00 amRNSBlocklisting Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.